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Abstract: Vandetanib (ZD6474) became the first systemic agent to be approved for the treatment 
of metastatic or locally advanced medullary thyroid cancer. It was a proof of principle, because 
it is an orally bioavailable medication that targets the growth factors felt to be important in the 
pathogenesis of this disease, ie, the rearranged during transfection proto-oncogene and vascular 
endothelial growth factor receptor. It was tested initially in two Phase II studies at doses of 
100 mg and 300 mg daily. Although activity was seen at both doses, the higher dose was 
chosen for a randomized, placebo-controlled Phase II study. This trial, which accrued more than 
300 patients, showed a statistically significant benefit for the group taking vandetanib compared 
with those taking placebo medication. Progression-free survival for the vandetanib arm has 
not been reached, compared with 19 months for the placebo arm. The main toxicity appears 
to be diarrhea, although some patients experienced significant side effects, including torsades 
de pointes and sudden cardiac death. Therefore, it is now necessary for practitioners to enroll 
in a Risk Evaluation Mitigation Strategy before being allowed to prescribe this medication, to 
reduce the risk of serious side effects occurring.
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Introduction
Medullary thyroid cancer (MTC) accounts for 3%–12% of thyroid cancer cases in 
most series. It arises from the C (parafollicular) cells, and does not occur because of 
radiation exposure, which has been identified as a risk factor for the development of 
papillary thyroid cancer.1 The disease was first described in the 1950s.2 Most cases 
are still sporadic (60%–70%), but the familial syndrome and association with other 
disorders, including pheochromocytoma and primary hyperparathyroidism,3 have 
been extensively researched over the last 50 years. Multiple hereditary forms of this 
disease have since been described, including familial MTC and the multiple endocrine 
neoplasia syndromes (MEN 2A and MEN 2B).1,4–6 MEN 2A accounts for 60% of the 
hereditary forms, MEN 2B 5%, and FMTC 35%.7
Survival is dependent on the stage of MTC at diagnosis. This is one of the most 
significant prognostic factors on multivariate analysis. Historically, survival for patients 
with MTC requiring systemic therapy was 6–22 months.8 A review of more than 
1200 cases demonstrated a mean survival time after diagnosis of MTC of 8.6 (range 
0–29.6) years. Patients with tumors confined to the thyroid gland had a 10-year survival 
rate of 95.6%, whereas patients with regional stage disease had an overall survival 
rate of 75.5%. Patients with distant metastases at diagnosis had a poor prognosis, 
with only 40% surviving 10 years and an overall survival of around 36 months.9 OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Chemotherapeutic agents, such as doxorubicin and cisplatin, 
have been used in the treatment of   unresectable MTC with 
limited success, considerable toxicity, and responses lasting 
only 9–22 months.10
Recent advances in drug development have led to the 
synthesis of many new targeted agents that are inhibitors of 
specific growth factors or cell signaling pathways involved 
in the pathogenesis of MTC.11
Mutations in specific regions of the rearranged during 
transfection (RET) proto-oncogene have been described in 
patients with both familial and sporadic forms of MTC. RET 
encodes for a transmembrane growth factor receptor that is 
involved in cell signaling and ultimately the uncontrolled 
growth of malignant MTC cells. Therefore, RET represents 
an obvious target for specific drugs to treat unresectable 
forms of this disease.
Many cancers rely on angiogenesis or the formation of 
new blood vessels to enable growth of the primary tumor 
and metastasis to distant sites. Angiogenesis appears to 
be controlled by a variety of proteins, including vascular 
endothelial growth factor (VEGF) and its specific receptor 
(VEGFR) on the cell surface. Because these are often 
overexpressed in thyroid cancers, antiangiogenesis agents 
have been developed as targeted treatments. Vandetanib 
(ZD6474, CaprelsaTM, AstraZeneca) targets both the RET 
proto-oncogene and the VEGF receptor, and is described in 
detail in this review.
Targets of vandetanib: RET and 
VEGF
ReT proto-oncogene
RET was first discovered in patients with MEN syndromes,12 
although it was not until 1985 that a new human transforming 
gene was detected by transfection of NIH 3T3 cells with a 
lymphoma DNA.13 Subsequent work pinpointed mutations on 
chromosome 10, followed by the identification of germline 
mutations in the RET proto-oncogene, located at 10q11.2, in 
patients with MEN 2A, MEN 2B, and familial MTC.6
RET is now felt to be one of a number of receptor tyrosine 
kinases which are present on cancer cells. These glyco-
proteins, including RET, receive extracellular signals for 
processes as diverse as cell growth, differentiation, survival, 
and programmed cell death (Figure 1). In response to binding 
of extracellular ligands, receptor tyrosine kinases generally 
form homodimers or heterodimers. On dimerization, auto-
phosphorylation occurs, followed by intracellular signal 
transduction through effectors that recognize and interact 
with the phosphorylated form of the receptor tyrosine kinase. 
Although the downstream signaling pathways activated 
by these steps may be shared by different receptors, the 
ligand-receptor interaction itself is very specific. However, 
in some cases, high-affinity ligand-receptor tyrosine kinase 
interactions can be modulated by the presence of other, 
low-affinity, nonsignaling accessory molecules at the cell 
surface.14
veGF receptor
The VEGFR pathway is also important in the pathogenesis 
of MTC.15 Three transmembrane receptors mediate the 
angiogenic and lymphogenic effects of VEGF, ie, VEGFR-1, 
VEGFR-2, and VEGFR-3. Of these, VEGFR-2 is believed 
to play the primary role in endothelial cell proliferation, 
migration, survival, and induction of vascular permeability 
characteristic of neovascularization required for tumor 
growth and metastasis. VEGF proteins secreted by the 
tumor cell act as ligands for the VEGFR, and a complex 
feedback loop is involved in the stimulation of angiogenesis 
(Figure 2).16
Description of vandetanib
Vandetanib (N-[4-bromo-2-fluorophenyl]-6-methoxy-7- 
[(1-methylpiperidin-4-yl) methoxy] quinazolin-4-amine) is 
an oral anilinquinazoline compound with a molecular weight 
Extracellular ligands
(eg, VEGF)
Growth factor receptor
(eg, VEGF, RET) 
MTC cell 
Growth factor pathways 
resulting in cell growth, 
angiogenesis, metastasis, 
apoptosis
Figure  1  interaction  of  extracellular  ligands  with  growth  factor  receptors  on 
medullary thyroid cancer cells.
Abbreviations: MTC, medullary thyroid cancer; veGF, vascular endothelial growth 
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of 475 Da. It competes with ATP binding in the catalytic 
domain of several tyrosine kinases. Recombinant enzyme 
assays have shown it to be a potent inhibitor of VEGFR-2 
(50% inhibitory concentration [IC50] 40 nM), with additional 
activity against VEGFR-3 (IC50 110 nM), epidermal growth 
factor receptor (IC50 500 nM), and RET (IC50 130 nM) 
kinases. Further studies on human umbilical vein endothe-
lial cells have found vandetanib to be a potent inhibitor of 
proliferation of VEGFR-stimulated cells (IC50 60 nM) with 
higher doses necessary for epidermal growth factor receptor-
stimulated human umbilical vein endothelial cell prolifera-
tion (IC50 170 nM). Vandetanib showed excellent selectivity 
for these kinases compared with related receptor tyrosine 
kinases, such as platelet-derived growth factor receptor-β and 
c-kit.17–19 This activity profile made it an attractive choice as 
a treatment for patients with unresectable MTC.
Clinical studies involving vandetanib
Phase i studies
Phase I studies helped to establish the recommended dose 
of vandetanib. The first 77 patients were enrolled in the US 
and Australia. Adult patients with malignant solid tumors 
who were refractory to standard treatments or for whom no 
standard treatment existed were treated with a single oral 
vandetanib dose ranging from 50 mg to 600 mg, followed 
by a 7-day observation period (cycle 0). At the end of this 
period, they received once-daily treatment at the same dose 
level as cycle 0 for 28 days, and continued to receive further 
28-day cycles until evidence of progression or dose-limiting 
toxicity. Seventy-six patients had at least one adverse event, 
most occurring for the first time during the initial 28-day 
treatment period. The most common drug-related adverse 
events were diarrhea (n = 29), rash (n = 26), nausea (n = 15), 
hypertension (n = 14), fatigue (n = 14), anorexia (n = 10), 
acneiform rash (n = 9), and maculopapular rash (n = 8). 
  Drug-related adverse events that led to treatment discontinua-
tion were congestive heart failure, follicular rash, folliculitis, 
and prolonged QT interval (all n = 1).
There were 43 dose-limiting toxicities reported, 27 of 
which occurred during the dose-escalation phase and 16 
during the cohort expansion phase. Most of the 14 dose-
limiting toxicities reported within the first 35 days of the 
study (cycles 0 and 1) were at the 500 mg and 600 mg doses; 
three of eight patients at each dose experienced four and 
seven dose-limiting toxicities, respectively.   Asymptomatic 
QTc prolongation was seen at the 500 mg and 600 mg dose 
levels; consequently, 300 mg was the highest dose used 
during the cohort expansion phase of the study. Seven 
patients experienced QTc prolongation, although all occur-
rences were asymptomatic (n = 1 in the 100 mg, 300 mg, 
and 600 mg groups, and n = 2 in the 200 mg and 500 mg 
groups). Pharmacokinetic studies in this trial showed van-
detanib to be extensively distributed, with a half-life of 
approximately 120 hours and a minimum of 28 days of con-
tinuous oral dosing required to achieve steady-state plasma 
concentrations.20 The second Phase I study was conducted 
in Japan, and enrolled 18 patients.21 Again, 300 mg daily 
was determined to be the recommended dose, with a similar 
toxicity profile and pharmacokinetic findings.
Studies involving vandetanib and MTC
Single-arm Phase ii studies
Germline mutations of RET cause the hereditary forms of 
MTC. Because RET is one of the main targets of vandetanib, 
two single-arm Phase II clinical trials were developed to 
evaluate the clinical utility of this agent in hereditary MTC 
(see Table 1). The first of these studies enrolled patients 
with unresectable, locally advanced, or metastatic MTC 
with a confirmed clinical diagnosis of MEN 2A, MEN 2B, 
or familial MTC and a germline RET mutation. They were 
Pathways
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Ras, Raf, 
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Cell survival 
Actin reorganization 
Gene expression 
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Figure 2 interaction of ligands with vascular endothelial growth factor receptor.
Abbreviations: veGF, vascular endothelial growth factor; veGFR, vascular endothelial 
growth factor receptor; ReT, rearranged during transfection; Pi3K, phosphoinositide 
3-kinase; MeK, mitogen-activated protein kinase kinase; PiP, phospholipase inhibitor 
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treated at an initial dose of 300 mg daily. Inclusion criteria for 
this study included at least one measurable lesion according 
to Response Evaluation Criteria in Solid Tumors (RECIST) 
guidelines, World Health Organization performance status 
0–2, and adequate cardiac, hematopoietic, hepatic, and renal 
function. This was an open-label Phase II study conducted at 
seven centers worldwide, and patients received vandetanib at a 
daily dose of 300 mg until progression of disease, withdrawal 
of consent, or unacceptable toxicity. The primary endpoint 
was objective response by RECIST, and secondary endpoints 
included duration of response, disease control, progression-
free survival, safety, and tolerability, as well as changes in 
serum levels of calcitonin and the glycoprotein carcinoembry-
onic antigen, which are both secreted by MTC cells. Thirty 
patients were enrolled from November 2004 to August 2006, 
and at the time of data cutoff (February 22, 2008), 17 patients 
were still continuing on treatment. Four patients had disease 
progression by RECIST but were reaping clinical benefits and 
allowed to remain on study. The remaining patients discon-
tinued vandetanib because of adverse events (n = 7), disease 
progression (n = 4), or withdrawal of consent (n = 2). The 
majority of patients had MEN 2A disease, and 29 of the 30 
had evidence of metastatic disease at presentation. Twenty 
percent of subjects (n = 6) achieved a partial response, and 
another 53% had stable disease for more than 24 weeks. 
The median duration of response was 10.2 (range 1.9–16.9) 
months, confidence interval (CI) 8.0–13.2 months. The major-
ity of patients (80%) had reductions in calcitonin levels to less 
than half their baseline values for at least 4 weeks.22
The second of the two Phase II trials had similar eligibil-
ity criteria. However, in this study, a lower dose of the drug 
(100 mg) was chosen as monotherapy in patients with locally 
advanced or metastatic familial forms of MTC. The primary 
objective again was to assess the objective response rate with 
vandetanib, according to RECIST criteria. In this study, if 
disease progression was noted on imaging, a post-progression 
treatment phase was allowed. If the investigator believed 
that there may have been clinical benefit from therapy, then 
patients could enter post-progression treatment with vande-
tanib at a higher dose of 300 mg/day until objective disease 
progression occurred at this dose, or until another withdrawal 
criterion was met. Nineteen patients were recruited between 
August 2006 and May 2007; initially, all received 100 mg 
daily. At the time of data cutoff, 11 were continuing on this 
dose, and the remaining patients had discontinued initial treat-
ment. Four of these patients had disease progression, and all 
entered post-progression treatment with vandetanib 300 mg 
daily. There were no complete responses; three (16%) were 
partial responders, and 10 patients had stable disease for 
24 weeks or longer. In this study, disease control was seen in 
68% of all patients (including complete and partial responders 
and those who had stable disease for longer than 24 weeks). 
Toxicities were manageable in both trials, with the most com-
mon adverse events being diarrhea, rash, and asymptomatic 
QTc prolongation on electrocardiogram. Seven patients in the 
trial using 300 mg discontinued treatment because of adverse 
events, five of which were felt by the investigator to be related 
to vandetanib (acne, hemorrhagic diarrhea, QTc prolongation, 
abnormal renal function, and nausea).23 Although it could be 
seen from both trials that 100 mg and 300 mg daily of van-
detanib had activity in this disease, no direct comparison of 
these dose levels has been conducted. The level chosen for 
the randomized placebo-controlled study was 300 mg daily.
Phase ii/iii randomized placebo-controlled trial
The encouraging results of these single-arm trials spurred 
accrual onto an international randomized Phase II/III trial 
known as ZETA (Zactima Efficacy Study versus Tarceva) 
comparing ZD6474 (vandetanib) and placebo in patients with 
inherited and sporadic forms of MTC.24 In this large trial, 
331 adults with unresectable locally advanced or metastatic 
MTC were randomized in a 2:1 manner to receive either 
ZD6474 at a dose of 300 mg daily, or placebo. Between 
December 2006 and November 2007, 231 subjects were 
assigned to vandetanib and 100 received placebo. The major-
ity of patients had sporadic disease (90%), metastatic disease 
(95%), and tumors that were positive for a RET mutation 
(56%). Patients were followed until disease progression, at 
which time they were unblinded and had the option to receive 
vandetanib in an open-label trial; if they chose open-label 
Table 1 Studies evaluating the use of vandetanib in medullary thyroid cancer
Study phase Initial vandetanib dose Percentage with partial  
response or better
Progression-free survival Reference
ii 300 mg 20 10.2 months 22
ii 100 mg 16 Not reported 23
Randomized ii/iii 300 mg 45 Not reached 24OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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vandetanib, they were then followed for survival. The median 
duration of treatment was 90.1 weeks in the vandetanib arm 
and 39.9 weeks in the placebo arm. The primary objective 
of the ZETA study was demonstration of improvement in 
progression-free survival on vandetanib compared with 
placebo. Other endpoints included evaluation of overall 
survival and   objective response rate.
Two-year follow-up results showed that 37% of the 
patients had progression, and 15% had died. The primary 
endpoint of the study, ie, progression-free survival, was 
met, with the researchers reporting a hazards ratio (HR) 
of 0.46 (95% CI: 0.31–0.69). The median progression-free 
survival was 19.3 months in the placebo group, and had not 
yet been reached in the vandetanib arm at the time of data 
presentation at the 14th International Thyroid Congress in 
2010. A significant improvement in progression-free survival 
was observed for patients randomized to receive vandetanib 
(HR: 0.35, 95% CI: 0.24–0.53; P , 0.0001). While the 
progression-free survival data led to United States Food and 
Drug Administration (FDA) approval, no significant overall 
survival difference was noted in the two arms because of the 
crossover design of the study.
Vandetanib was also associated with statistically signifi-
cant advantages in the secondary endpoints, such as objective 
response rate (45% vs 13%; odds ratio [OR]: 5.4); disease 
control rate of 24 weeks or more (OR: 2.64); calcitonin 
biochemical response (OR: 72.9); carcinoembryonic antigen 
biochemical response (OR: 52); and time to worsening of 
pain (HR: 0.61). Some of the radiological responses were 
dramatic. At this time, it is not known whether any biochemi-
cal, radiological, or clinical parameters significantly predict 
response. Data are also not yet available on whether certain 
metastatic sites respond better than others. In the placebo arm, 
12 of 13 responses occurred after the patients had received 
open-label vandetanib. Adverse events were more common 
with vandetanib than on placebo, including diarrhea (56% 
vs 26%), rash (45% vs 11%), nausea (33% vs 16%), hyper-
tension (32% vs 5%), and headache (26% vs 9%). The most 
severe toxicities were QT prolongation, torsades de pointes, 
and sudden death, which are addressed in a boxed warning 
in the prescribing information.
Based on these results, Astra Zeneca filed for FDA approval 
of the drug in the US and the European Medicines Agency in 
Europe late in 2010, receiving an orphan drug designation by 
the FDA on December 2, 2010, with final approval granted 
on April 6, 2011.25 The approval was specifically for patients 
who are ineligible for surgery and have disease that is growing 
or causing symptoms. The benefits of the drug in patients 
who have occult or micrometastatic disease but with a rapid 
calcitonin doubling time are not known.
The severe cardiac side effects mentioned previously are 
addressed in a boxed warning in the prescribing information. 
Vandetanib has a prolonged half-life of 19 days, so electrocar-
diograms and levels of serum potassium, calcium,   magnesium, 
and thyroid-stimulating hormone are recommended to be 
obtained at baseline, at 2–4 weeks, and at 8–12 weeks after 
starting treatment, and every 3 months thereafter as long as the 
patient remains on treatment. As a result of the FDA concern 
about toxicity, only US prescribers and pharmacies certified 
through the Vandetanib Risk Evaluation Mitigation Strategy 
(REMS) program, ie, a restricted distribution program, are 
able to prescribe and dispense vandetanib.
Clinical utility of vandetanib in the 
treatment of MTC
Vandetanib became the first systemic agent to be approved 
for the treatment of locally advanced or metastatic MTC. 
Therefore, it represents a new standard of care for these 
patients. However, MTC can be an indolent disease, and 
subsequent studies have demanded that patients have radio-
graphic progression of disease prior to enrollment, such as 
the randomized Phase III study of XL-184. Some patients 
may have a symptom-free existence for many years on 
observation alone, and therefore are unlikely to gain much 
benefit from the addition of a systemic agent. The potentially 
serious cardiac side effects call for caution in prescribing this 
medication to otherwise asymptomatic individuals. The less 
serious but quality-of-life altering effects, such as acneiform 
rash and nausea, also deter some patients and physicians 
from starting the drug immediately on signs of biochemi-
cal progression of disease. The high cost of a new tyrosine 
kinase inhibitor is also likely to limit the number of patients 
who may have access to this medication. However, some 
patients could gain significant benefit; these include those 
with clear radiographic progression or significant symptoms 
related to their disease, those who have no or limited cardiac 
histories, and those who are reliable enough to comply with 
close follow-up. By closely monitoring of electrolyte levels 
and electrocardiograms, the authors have found it possible to 
avoid any cardiac events in their patient population to date.
Resistance may also arise in tumors exposed to vandetanib. 
The authors speculate that there may be many reasons for 
this, including new molecular abnormalities involving RET 
or other receptors, such as loss of expression, genomic OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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amplification, or the activation of alternative downstream 
signaling pathways. Further work needs to be done to 
elucidate which of these is most important. The combination 
of vandetanib and other drugs may help delay or overcome 
some resistance mechanisms. Many such drugs have been 
evaluated in MTC and other forms of thyroid cancer with 
varying degrees of success.26–35
Conclusion
Vandetanib has emerged as an effective targeted therapy in 
the treatment of MTC. Its recent FDA approval for patients 
with metastatic or unresectable disease is a landmark in 
the history of this condition. Its development as a targeted 
agent and the results of Phase II and randomized studies 
have become a proof of principle. Future studies involving 
combinations with other systemic agents are eagerly awaited 
and may further improve upon the significant results seen to 
date with this agent.
Disclosure
HAD sits on the advisory board for Astra Zeneca (mock 
Oncologic Drugs Advisory Committee meeting).
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